Status and phase
Conditions
Treatments
About
Rationale: RAS 130 is an anti-diabetic agent used to lower the blood glucose level in Type II Diabetes mellitus (non-insulin-dependent diabetes) patients with proper diet and exercise. RAS 130 works by restoring proper response to insulin in the body. RAS 130 acts primarily by increasing insulin sensitivity which improves glycemic index. It is presumed that RAS 130 does not cause cardiovascular side effects if it is given to Type II diabetes mellitus patients leading a healthy life style. Specifically, controlling diet is done according to American Diabetic Association & American Heart Association guidelines and also through doing aerobic exercises. Guideline for aerobic exercise is given in the design of the study.
Exercise is helpful in controlling body weight which can lower the risk for heart disease. Diabetes itself is one of the compounding factors for heart diseases. Exercise helps lowering the LDL cholesterol and raising the HDL cholesterol which is required to prevent heart diseases and achieve a better quality of life.
Purpose: The aim of this study is to prospectively assess and evaluate the cardiovascular side effects and reduction of blood glucose levels in the Type II Diabetes mellitus patients treated with RAS 130, who either met, or failed to meet criteria for diet and exercise.
Full description
Objectives:
Primary Objective:
To determine the relatedness of cardio toxicity as a side effect in subjects with DM II who are treated with RAS 130 who either met, or failed to meet the criteria for diet and exercise.
Hypothesis I: There will be no evidence of cardiovascular side effects in subjects who are determined to have maintained proper diet and exercise "healthy lifestyle" throughout the study.
Hypothesis II: There may be evidence of cardiovascular side effects in subjects who are determined to neglect proper diet and exercise "unhealthy lifestyle" throughout the study.
Secondary Objective:
To determine the effectiveness of RAS 130 on the reduction of blood glucose levels in subjects with DM II.
Hypothesis III: RAS 130 will be effective in reducing blood glucose levels as a single agent.
Hypothesis IV: RAS 130 will be effective in reducing blood glucose in combination with other anti- diabetic agents.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subject unable to give Informed Consent
Patients with Type I Diabetes Mellitus
a. History of ketoacidosis
Serum creatinine > 2.0 mg or above
Liver Function Test; Elevated liver enzymes: ALT/AST (2.5 times the upper limit of the reference range), Bilirubin Testing - Accept three fold, A/G ratio - Accept two fold
Hypercholesterolemia (more than 300mg)
Myocardial Infarction (MI) within 6 months
Severe or unstable angina
Elevated triglycerides >500 mg/dL
Abnormal EKG reading
Abnormal assessment in stress Echocardiography (ultrasound imaging)for Left Ventricular ejection fraction for congestive heart failure
Anemia (Hb <11 g/dl for men or <10 g/dl for women)
Blood Dyscrasia, Decrease in Hematocrit - Accept two fold, Low WBC count - Accept one fold, Decrease platelet count - Accept three fold
Macular edema/ macular degeneration
Patients who are taking insulin
Subjects with systolic blood pressure >170 mmHg or diastolic blood pressure >90 mmHg
Active participation in another trial
Subject physically unable to perform exercise due to neurologic or orthopedic conditions.
Patients taking antipsychotic medications.
Subjects testing positive for the illicit drugs (cocaine, amphetamines, heroin)
Subjects who smoke tobacco products
Females who are lactating, pregnant, or planning to become pregnant
Signs and symptoms of Congestive heart failure (such as shortness of breath or swelling in upper extremities)
History of severe edema or a medically serious fluid retention
Primary purpose
Allocation
Interventional model
Masking
460 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal